Trinity Biotech PLC Sample Contracts
RecitalsPurchase Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
WARRANTWarrant Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
EXHIBIT 99.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of this 27th day of November, 2002 by and among TRINITY BIOTECH PLC, a corporation organized under the laws of the Republic of...Registration Rights Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4b.1 LEASE AGREEMENT BETWEEN RONAN O'CAOIMH, JONATHON O'CONNELL AND JIM WALSH WITH TRINITY BIOTECH PLC IN RESPECT OF WAREHOUSE PREMISES IN BRAY, CO WICKLOW, IRELAND. THIS LEASE made the 18 day of October 2004 BETWEEN (a) LANDLORD: RONAN...Lease Agreement • March 31st, 2006 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
TRINITY BIOTECH PLC Issuer AND [TRUSTEE], TrusteeIndenture • June 28th, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
INDENTURE, dated as of , 20 , among Trinity Biotech PLC, a public limited company incorporated under the laws of Ireland (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
EXHIBIT 4b.2 LEASE AGREEMENT BETWEEN RONAN O'CAOIMH AND JIM WALSH WITH TRINITY BIOTECH MANUFACTURING LIMITED IN RESPECT OF OFFICE PREMISES IN BRAY, CO WICKLOW, IRELAND THIS INDENTURE made the 26 day of November 2004 B E T W E E N RONAN O'CAOIMH of...Lease Agreement • March 31st, 2006 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
EXHIBIT 99.2 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS...Convertible Note • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
AT THE MARKET OFFERING AGREEMENTAt the Market Offering Agreement • July 12th, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
Trinity Biotech plc, a public limited company incorporated under the laws of Ireland (the “Company”), confirms its agreement (this “Agreement”) with Craig-Hallum Capital Group LLC (the “Manager”) as follows:
AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Deposit Agreement Dated as of October 21, 1992 As Amended and Restated as of _______________, 2004Deposit Agreement • January 15th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
DEPOSIT AGREEMENT dated as of October 21, 1992, as amended and restated as of _____________, 2004 among Trinity Biotech plc, incorporated under the laws of the Republic of Ireland (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation (herein called the Depositary), and all Owners and holders from time to time of American Depositary Receipts issued hereunder.
1 THIS AGREEMENT is made on 31 October, 1996. BETWEEN: (1) ENVIROMED PLC is a company incorporated in England and Wales (Registered No. 2815159) and having its registered office at Mercury House, 195 Knightsbridge, London SW7 1YE ("Enviromed"); (2)...Not Specified in the Provided Text • December 9th, 1996 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • England
Second Amendment to Credit Agreement and GuarantyCredit Agreement and Guaranty • November 15th, 2022 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
CREDIT AGREEMENT AND GUARANTY, dated as of December 15, 2021 (this “Agreement”), among TRINITY BIOTECH, INC., a Delaware corporation (“U.S. Holdings”), FITZGERALD INDUSTRIES INTERNATIONAL, INC., a Delaware corporation (“U.S. Fitzgerald”) CLARK LABORATORIES, INC. (d/b/a Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), BIOPOOL US INC., a Delaware corporation (d/b/a Trinity Biotech Distribution) (“U.S. Biopool”), PRIMUS CORPORATION, a Missouri corporation (“U.S. Primus”), MARDX DIAGNOSTICS, INC., a California corporation (“U.S. MarDx”), IMMCO DIAGNOSTICS, INC., a Delaware corporation (“U.S. Immco” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Biopool, U.S. Primus and U.S. MarDx, each a “Borrower” and collectively, the “Borrowers”), certain Guarantors from time to time parties hereto, the lenders from time to time party hereto (each, as a “Lender” and collectively, the “Lenders”), and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (“Pe
Exhibit A to Deposit AgreementDeposit Agreement • January 15th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
The Bank of New York as depositary (hereinafter called the "Depositary"), hereby certifies that _____________________________________________________________ ___________________________________________________, or registered assigns IS THE OWNER OF ___________________________
Fifth Amended and Restated Credit Agreement and GuarantyCredit Agreement • May 15th, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTED BY AMERICAN DEPOSITARY RECEIPTS TRINITY BIOTECH PLCSecurity Agreement • May 16th, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This Warrant is issued pursuant to that certain Side Letter, dated as of the date hereof, by and between the Company and the Holder.
Second Amended and Restated Credit Agreement and GuarantyCredit Agreement • February 1st, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTED BY AMERICAN DEPOSITARY RECEIPTS TRINITY BIOTECH PLCSecurity Agreement • March 21st, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This Warrant is issued pursuant to that certain Side Letter, dated as of the date hereof, by and between the Company and the Holder.
LEASE AGREEMENTLease Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
LORRELLE S. JOHNSON and SHARON L. JOHNSON, of 3094 North Main Street Extension, Jamestown, New York 14701, hereinafter referred to as “Johnson,”
SENIOR CONVERTIBLE NOTEConvertible Security Agreement • December 23rd, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This Senior Convertible Note (including all Senior Convertible Notes issued in exchange, transfer or replacement hereof, and as any of the foregoing may be amended, restated, supplemented or otherwise modified from time to time, this “Note”) is one of the Senior Convertible Notes issued pursuant to the Credit Agreement (collectively, including all Senior Convertible Notes issued in exchange, transfer or replacement thereof, and as any of the foregoing may be amended, restated, supplemented or otherwise modified from time to time, the “Notes”). All capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Credit Agreement.
Exhibit A to Deposit AgreementDeposit Agreement • January 15th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
The Bank of New York as depositary (hereinafter called the "Depositary"), hereby certifies that _____________________________________________________________ ___________________________________________________, or registered assigns IS THE OWNER OF ___________________________
JOINT FILING AGREEMENT and POWER OF ATTORNEYJoint Filing Agreement • October 17th, 2008 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
The undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including any amendments thereto) with respect to the American Depository Receipts of Trinity Biotech plc beneficially owned by each of them to the extent that they may be deemed to be acting as a group, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. The undersigned further agree that each of them is (i) individually eligible to use the Schedule 13D to which this Exhibit is attached and (ii) responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness of accuracy of the information concerning any other person making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any n
First Amendment to Amended and Restated Credit Agreement and GuarantyCredit Agreement • April 24th, 2023 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This First Amendment to Amended and Restated Credit Agreement and Guaranty, dated as of April 20, 2023 (this “First Amendment”), is entered into by and among TRINITY BIOTECH, INC., a Delaware corporation (“U.S. Holdings”), FITZGERALD INDUSTRIES INTERNATIONAL, INC., a Delaware corporation (“U.S. Fitzgerald”), CLARK LABORATORIES, INC. (d/b/a Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), BIOPOOL U.S., INC., a Delaware corporation (d/b/a Trinity Biotech Distribution), (“U.S. Biopool”), PRIMUS CORPORATION, a Missouri corporation (“U.S. Primus”), MARDX DIAGNOSTICS, INC., a California corporation (“U.S. Mardx”), IMMCO DIAGNOSTICS, INC., a Delaware corporation (“U.S. Immco” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Biopool, U.S. Primus and U.S. Mardx, each a “Borrower” and collectively, the “Borrowers”), the Guarantors party hereto, the Lenders party hereto and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership, as Lender and as adminis
AGREEMENT AND PLAN OF MERGERMerger Agreement • April 9th, 2014 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of July 26, 2013 by and among: (i) IMMCO Diagnostics, Inc., a Delaware corporation (the “Company”); (ii) Trinity Biotech PLC, an Irish public limited company (“Parent”), (iii) Trinity Biotech, Inc., a Delaware corporation (the “Buyer”); (iv) TRIB Acquisition Corp., a Delaware corporation (“Merger Sub”); and (v) Summit Partners Venture Capital Fund II-A, L.P., Summit Partners Venture Capital Fund II-B, L.P., and Summit Investors VI, L.P., each a Delaware limited partnership (collectively, “Summit Partners”), solely in their collective capacity as the Representative hereunder.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 11th, 2022 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:
SHARE PURCHASE AGREEMENT between Goldcup 7149 AB, changing name to Trinity Biotech Sweden AB and et al regarding the shares in Fiomi Diagnostics ABShare Purchase Agreement • April 6th, 2012 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 23rd, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 22, 2025, by and among Trinity Biotech PLC, a public limited company organized and existing under the laws of Ireland (the “Company”), Perceptive Credit Holdings III, L.P. (“PCH III”) and Perceptive Credit Holdings II, L.P. (“PCH II” and, together with PCH III the “Initial Investors” and each an “Initial Investor”) and each other investor from time to time signatory hereto (together with the Initial Investors and any transferee or assignee who agrees in writing to become bound by the provisions of this Agreement in accordance with Section 10 hereof, the “Investors” and each an “Investor”).
ContractEmployment Agreement • May 16th, 2023 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This Employment Agreement (this "Agreement") is entered into as of October 3, 2022 between Aris Kekedjian ("Employee") and Trinity Biotech, Inc. ("Trinity" or the "Company").
CONVERSION RIGHTS AGREEMENTConversion Rights Agreement • December 23rd, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
This CONVERSION RIGHTS AGREEMENT (this “Agreement”) is entered into as of December 22, 2025, by and among Trinity Biotech PLC, a public limited company organized and existing under the laws of Ireland (“Parent” or the “Company”), TRIB Biosensors Inc., a Delaware corporation (“TRIB B” and together with Parent, the “Trinity Parties” and each a “Trinity Party”), and Perceptive Credit Holdings II, L.P., (together with its successors and assigns, the “Holder”). The Trinity Parties and the Holder are sometimes referred to herein, collectively, as the “Parties” and each as a “Party.” Capitalized terms used and not otherwise defined herein shall have the meanings given to them in the Purchase Agreement (as defined below); except that any capitalized terms used in Section 2 of this Agreement and not otherwise defined herein shall have the meanings given to them in the form of Senior Convertible Note (the “Note”) attached as Exhibit A to that certain Second Amendment to Credit Agreement, dated a
STOCK PURCHASE AGREEMENTStock Purchase Agreement • June 16th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Deposit Agreement Dated as of October 21, 1992 As Amended and Restated as of _______________, 2004Deposit Agreement • January 15th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
DEPOSIT AGREEMENT dated as of October 21, 1992, as amended and restated as of _____________, 2004 among Trinity Biotech plc, incorporated under the laws of the Republic of Ireland (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation (herein called the Depositary), and all Owners and holders from time to time of American Depositary Receipts issued hereunder.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACES WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIALTransition Agreement • April 30th, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
TRANSITION AGREEMENT (this “Agreement”), dated as of December 20, 2023, among Bayer Healthcare LLC, a Delaware limited liability company (“Bayer”), WaveForm Technologies, Inc. a Delaware corporation (“WaveForm”), and TRIB Biosensors Inc., a Delaware corporation (“Trinity”).
TRINITY BIOTECH INVESTMENT LIMITED, as Issuer TRINITY BIOTECH PLC, as Guarantor WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee 4.00% Exchangeable Senior Notes due 2045 INDENTURE Dated as of April 9, 2015Indenture • April 9th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
INDENTURE, dated as of April 9, 2015, among Trinity Biotech Investment Limited, an exempted limited liability company incorporated under the laws of the Cayman Islands, as issuer (the “Company”), Trinity Biotech plc, a public limited company incorporated under the laws of Ireland, as Guarantor (the “Guarantor”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”).
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTED BY AMERICAN DEPOSITARY RECEIPTS TRINITY BIOTECH PLCSecurity Agreement • August 12th, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This Warrant is issued pursuant to that certain Sixth Amended and Restated Credit Agreement and Guaranty dated as of August 7, 2025 (the “Credit Agreement”) by and among Trinity Biotech, Inc., a Delaware corporation (“U.S. Holdings”), Fitzgerald Industries International, Inc., a Delaware corporation (“U.S. Fitzgerald”), Clark Laboratories, Inc. (d/b/a as Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), MarDx Diagnostics, Inc., a California corporation (“U.S. MarDx”), Biopool U.S., Inc., a Delaware corporation (d/b/a Trinity Biotech Distribution) (“U.S. Biopool”), Primus Corporation, a Missouri corporation (“U.S. Primus”), IMMCO Diagnostics, Inc., a Delaware corporation (“U.S. Immco”), TRIB Biosensors Inc., a Delaware corporation (“U.S. TRIB” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Mardx, U.S. Biopool, U.S. Primus and U.S. Immco, each a “Borrower” and collectively, the “Borrowers”), certain guarantors party thereto from time to time, the lenders
FINANCIAL ADVISORY AGREEMENTFinancial Advisory Agreement • November 29th, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
The purpose of this letter (the “Agreement”) is to confirm the engagement of Craig-Hallum Capital Group LLC (“Advisor”) by Trinity Biotech plc (the “Company”) to render financial advisory services to the Company.
Sixth Amended and Restated Credit Agreement and GuarantyCredit Agreement • August 12th, 2025 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
SUBLEASE AGREEMENTSublease Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
THIS SUBLEASE AGREEMENT, made and entered into on December 1, 2007 by and between 60 PINEVIEW LLC, organized and existing under and by virtue of the laws of the state of New York having its principal office at 60 Pineview Drive, Amherst, New York 14228 (the “Sublessor”) and IMMCO DIAGNOSTICS, INC., organized and existing under and by virtue of the laws of the State of New York with its address at 60 Pineview Drive, Amherst, New York 14228 (the “Sublessee”).